Lankenau Institute for Medical Research
http://www.limr.org/Overview
Investors 1
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 10
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 30, 2012 | Biotech startup developing nanoparticles for cancer treatment and improving accuracy of tests | Lankenau also wants to use the therapeutic delivery to go after cells that cause post cataract surgery eye lesions. Earlier this year, Genisphere and Lankenau initiated a collaboration to develop better tools to diagnose Crohn’s disease and... |
| Jun 20, 2012 | Joint fluid testing firm using biomarkers to detect infection, disease raises $5M | Since Birkmeyer joined the company in March last year, the company has added 17 staff and expects to add another eight Ph.D.-level employees by the end of the year, consisting primarily of scientists and senior management. “When you have in... |
| Jan 31, 2012 | Pennsylvania human antibody cloning company raising $1.5 million | Dr. Scott K. Dessain, the founder and chief science officer of Immunome, is an associate professor with the Lankenau Institute for Medical Research in Wynnewood, Pennsylvania. The CEO of Immunome, Timothy Pelura, is a serial entrepreneur in... |
| Jan 11, 2012 | Alzheimer’s, back pain treatments, osteoarthritis diagnosis tech get fresh capital | Wynnewood, Pennsylvania-based CD Diagnostics‘ technology involves using biomarkers in synovial fluid to diagnose maladies such as osteoarthritis, rheumatoid arthritis, gout, pseudogout and lupus, according to literature from the company’s p... |
| Alzheimer’s, back pain treatments, osteoarthritis diagnosis tech get fresh capital | Five companies developing treatments for back pain, Alzheimer’s and Parkinson’s diseases, and innovative diagnosis technology to detect osteoarthritis and glaucoma have received fresh funding from the state’s economic development and invest... | |
| Pennsylvania human antibody cloning company raising $1.5 million | A Pennsylvania biotechnology company is raising $1.5 million to advance its human antibody cloning technology that it believes has broad applications for the treatment of unmet medical needs such as Alzheimer’s disease, cancer, infectious d... | |
| Five new life sciences startups at Philadelphia accelerator | Philadelphia’s University City Science Center’s Port business accelerator just announced it’s fostering some pretty interesting life sciences startups – ranging from cancer diagnostics to 3D bioprinting. Biobots In the vein of Organovo, reg... | |
| Joint fluid testing firm using biomarkers to detect infection, disease raises $5M | A firm that has developed joint fluid assays for orthopedic and rheumatology practices has raised just about all of its $5 million target to bring its tests to market. The first test, scheduled to launch in August, is to detect infection. O... | |
| Biotech startup developing nanoparticles for cancer treatment and improving accuracy of tests | A biotechnology startup is working with Lankenau Institute for Medical Research to develop nanotherapeutics for cancer and eye diseases in the latest in a series of collaborations forged by the suburban Philadelphia company. Genisphere, a H... |
Reviews 0
FAQ about Lankenau Institute for Medical Research
What has the press written about Lankenau Institute for Medical Research?
Parsers VC has collected 10 articles mentioning Lankenau Institute for Medical Research, among them “Biotech startup developing nanoparticles for cancer treatment and improving accuracy of tests” (Nov 30, 2012) and “Joint fluid testing firm using biomarkers to detect infection, disease raises $5M” (Jun 20, 2012).
Is Lankenau Institute for Medical Research still active?
Yes, Lankenau Institute for Medical Research is active; its latest activity on Parsers VC dates from Aug 10, 2015.